<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146111">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01661686</url>
  </required_header>
  <id_info>
    <org_study_id>COPAC</org_study_id>
    <nct_id>NCT01661686</nct_id>
  </id_info>
  <brief_title>Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures</brief_title>
  <acronym>COPAC</acronym>
  <official_title>A Randomized Comparison of a Fully Covered Self Expandable Metal Stent Versus a Partially Covered Self Expandable Metal Stent in Malignant Esophageal Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fully covered or partially covered metal
      stents are more favorable in incurable malignant stenosis of the esophagus or cardia.
      Primary outcome will be the occurence of recurrent dysphagia which is defined as dysphagia
      due to a stent or tumour related cause in a 6-month follow-up
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrent dysphagia.</measure>
    <time_frame>From stent placement (t=0) until death or placement of second stent, assessed up to 6 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is defined as occurrence of dysphagia due to a stent or tumor related cause. These include tumor in- or overgrowth, stent migration, stent fracture or food impaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success of SEMS placement</measure>
    <time_frame>At stent placement (t=0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success defined as improvement of dysphagia score</measure>
    <time_frame>From stent placement until death or placement of second stent, assessed up to 6 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>dysphagia scores will be obtained at time point: t=0, t= 1 week, t=2 weeks, t=1 month, t=3 months and t= 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and minor complication rate</measure>
    <time_frame>From stent placement until death or placement of second stent, assessed up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From stent placement until death or placement of second stent, assessed up to 6 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>This will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 and the EOS18, at time point: t=0, t= 1 week, t=2 weeks, t=1 month, t=3 months and t= 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From stent placement until death or placement of second stent, assessed up to 6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Esophageal Stenosis</condition>
  <arm_group>
    <arm_group_label>Insertion of a partially covered SEMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insertion of a Fully covered SEMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Partially covered SEMS</intervention_name>
    <description>Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available</description>
    <arm_group_label>Insertion of a partially covered SEMS</arm_group_label>
    <other_name>WallFlex Partially covered esophageal stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fully covered SEMS</intervention_name>
    <description>Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available</description>
    <arm_group_label>Insertion of a Fully covered SEMS</arm_group_label>
    <other_name>WallFlex Fully covered esophageal stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant stricture of the esophagus or cardia

          -  No curative treatment options available

          -  Dysphagia grade of at least 2 (i.e. swallow semi-solid foods or less)

          -  Informed consent

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  Previous treatment with self-expandable metal stent for same condition

          -  Evidence of tumor within 2 cm of the upper esophageal sphincter.

          -  Presence of an esophago-tracheal or -bronchial fistula or both.

          -  Not able to undergo upper endoscopy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco J Bruno, M.D., Prof</last_name>
    <role>Study Director</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manon CW Spaander, M.D., PhD</last_name>
    <phone>+31107035643</phone>
    <email>v.spaander@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Didden, M.D.</last_name>
    <phone>+31107040704</phone>
    <phone_ext>*3609</phone_ext>
    <email>p.didden@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IJsselland Hospital</name>
      <address>
        <city>Capelle a/d IJssel</city>
        <state>Zuid Holland</state>
        <zip>2900 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tang</last_name>
      <email>tjtang@ysl.nl</email>
    </contact>
    <investigator>
      <last_name>Thjon Tang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikazia Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ter Borg</last_name>
      <email>pcj.ter.borg@ikazia.nl</email>
    </contact>
    <investigator>
      <last_name>Pieter CJ ter Borg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Fransiscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leeuwenburg</last_name>
      <email>i.leeuwenburgh@sfg.nl</email>
    </contact>
    <investigator>
      <last_name>I Leeuwenburg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Zwijndrecht</city>
        <state>Zuid Holland</state>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolters</last_name>
      <email>L.M.M.Wolters@asz.nl</email>
    </contact>
    <investigator>
      <last_name>Leonieke MM Wolters, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon CW Spaander</last_name>
      <email>v.spaander@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Paul Didden</last_name>
      <email>p.didden@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Manon CW Spaander, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Foundation for Liver Research</investigator_affiliation>
    <investigator_full_name>Manon Spaander</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>esophageal stenosis</keyword>
  <keyword>stent</keyword>
  <keyword>endoscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
